Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05380635 · ClinicalTrials.gov registry record · Phase 2
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
A Phase 2 study, sponsored by Soligenix.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT05380635: Completed Phase 2 study, sponsored by Soligenix.
NCT05380635 is a Phase 2 study that has completed, run by Soligenix. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05380635, a Phase 2 study, has completed, sponsored by Soligenix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
To assess the blood levels of hypericin and any electrocardiogram (ECG) changes during 8 weeks of HyBryte (topical hypericin ointment) photodynamic therapy.
Primary Outcome
Assess any ECG QT interval changes (defined as any occurrences of QT interval \>500 ms or changes in QT interval \>60 ms) during standard HyBryte photodynamic therapy.
Interventions
- DRUG Hypericin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-05-09 |
| Est. Completion | 2022-08-16 |
| Phase | Phase 2 |
What the finished NCT05380635 record still lists
NCT05380635 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Hypericin is the first listed.
NCT05380635 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05380635 about?
NCT05380635 is a clinical study titled "PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma". To assess the blood levels of hypericin and any electrocardiogram (ECG) changes during 8 weeks of HyBryte (topical hypericin ointment) photodynamic therapy.
What is the current status of trial NCT05380635?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2022-05-09. Estimated completion is 2022-08-16.
What interventions are being tested in trial NCT05380635?
The interventions under investigation include: Hypericin (DRUG).
Who is sponsoring clinical trial NCT05380635?
This trial is sponsored by Soligenix, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05380635's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI